News &amp; Updates

Among women with low-risk ductal carcinoma in situ, the incidence of invasive cancer in the same breast does not appear to be different between those who have undergone active monitoring and those who have received a surgical procedure, according to the results of COMET trial.

Active monitoring safe for low-risk ductal carcinoma in situ

Blinatumomab plus chemo improves survival in paediatric B-ALL

Chemotherapy combined with blinatumomab (blin) delivers significant improvements in disease-free survival (DFS) in children with newly diagnosed National Cancer Institute standard risk (SR) B-cell acute lymphoblastic leukaemia (B-ALL), according to the results of the AALL1731 study presented at ASH 2024.

Blinatumomab plus chemo improves survival in paediatric B-ALL

Tafasitamab plus lenalidomide, rituximab boosts PFS in follicular lymphoma

The addition of tafasitamab (tafa) to lenalidomide and rituximab (len+R) significantly improves progression-free survival (PFS) in patients with relapsed or refractory (R/R) follicular lymphoma (FL), as shown in a phase III study presented at ASH 2024. The safety profile of this combination is manageable and consistent with expected toxicities.

Tafasitamab plus lenalidomide, rituximab boosts PFS in follicular lymphoma

Survival benefit with STRIDE for HCC sustained at 5 years

The updated exploratory analysis of the phase III HIMALAYA trial demonstrates a significant overall survival (OS) benefit at 5 years with the STRIDE* regimen comprising tremelimumab and durvalumab for patients with unresectable hepatocellular carcinoma (HCC).

Survival benefit with STRIDE for HCC sustained at 5 years

10 Jan 2025

LITESPARK-005 update: Belzutifan benefits East Asians with advanced RCC

Treatment with belzutifan improves progression-free survival (PFS) and objective response rate (ORR) in East Asian patients with advanced clear-cell renal cell carcinoma (RCC) compared with everolimus, according to the updated subgroup data of the phase III LITESPARK-005 trial presented at ESMO Asia 2024.

LITESPARK-005 update: Belzutifan benefits East Asians with advanced RCC

Ipsilateral breast cancer recurrence in ‘good-risk’ DCIS reduced with tamoxifen

09 Jan 2025 by

Adjuvant use of tamoxifen is associated with a big drop in the risk of recurrence in the same breast among patients with “good-risk” ductal carcinoma in situ (DCIS) after breast-conserving surgery without radiotherapy.

Ipsilateral breast cancer recurrence in ‘good-risk’ DCIS reduced with tamoxifen

Muscle loss persists in leukaemia patients on nutrition therapy

Muscle or fat-free mass (FFM) decreases in patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) undergoing intensive chemotherapy despite medical nutrition therapy (MNT), reports a recent study. Fat mass, on the other hand, remains unchanged.

Muscle loss persists in leukaemia patients on nutrition therapy

Oral bacteria a risk factor for HNSCC development

09 Jan 2025 by

A prospective nested case-control study yields compelling evidence that oral bacteria are a risk factor for the development of head and neck squamous cell carcinoma (HNSCC), which comprises cancers of the oral cavity, pharynx, and larynx.

Oral bacteria a risk factor for HNSCC development